Related Experiment Video
Updated: Sep 16, 2025
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
Platelet Membrane-Coated Poly (Lactic-Co-Glycolic Acid) Nanoparticles as a Targeting Drug Delivery System for
Bomin Song1, Young-Guk Na1, Byung Jin Kim1
1College of Pharmacy, Chungnam National University, Daejeon, 31434, Republic of Korea.
International Journal of Nanomedicine
|July 7, 2025
Summary
This study developed novel nanoparticles that improve paclitaxel delivery for cancer treatment. The new nanoparticles target tumors, overcome drug resistance, and reduce toxicity, showing promise for advanced cancer therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Drug Delivery Systems
Background:
- Paclitaxel (PTX) efficacy is limited by poor solubility, P-glycoprotein (P-gp) efflux, and non-specific toxicity.
- Developing effective nanocarriers is crucial for overcoming these limitations in chemotherapy.
Purpose of the Study:
- To develop a triple-functionalized nanocarrier system (PTPNs) for enhanced paclitaxel delivery.
- To improve tumor targeting, overcome multidrug resistance, and reduce systemic toxicity of paclitaxel.
Main Methods:
- Fabrication of poly(lactide-co-glycolide) nanoparticles (PNs) coated with platelet membrane (PM) and modified with D-α-tocopheryl polyethylene glycol succinate (TPGS).
- Characterization of PTPNs using particle size analysis, TEM, and protein assay.
- In vitro drug release studies, cytotoxicity assays in multidrug-resistant cells, and in vivo biodistribution and xenograft studies.
Main Results:
- PTPNs showed a particle size of 221 nm with successful PM coating.
- Sustained PTX release was observed in acidic tumor microenvironment conditions.
- PTPNs demonstrated a 17-fold reduction in PTX IC50 in resistant cells and enhanced tumor accumulation in vivo, significantly reducing tumor burden.
Conclusions:
- The PTPNs system effectively enhances paclitaxel delivery by improving tumor specificity and overcoming multidrug resistance.
- This biomimetic nanocarrier approach shows significant potential for advancing cancer therapy by reducing systemic toxicity.
